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Who’s at Risk?
Gauging Susceptibility to Air Pollutants
What makes one individual more susceptible than another to the 
harmful effects of air pollution? If particulate matter (PM) differen-
tially affects certain populations, which factors or characteristics are 
most likely to account for the heightened risk? These are the questions 
behind a new review of studies that examined various characteristics 
linked with susceptibility [EHP 119(4):446–454; Sacks et al.].
To assess the differential effects of PM on specific populations, 
epidemiologic studies often conduct stratified analyses; a stronger 
association between PM and the health effect being measured in one 
subgroup compared with another provides evidence for a more sus-
ceptible population. Additional insight can be gleaned via controlled 
human exposure studies (which examine individuals with a preexist-
ing disease) and toxicologic studies using animal models of disease. 
The authors of the current study integrated these various lines of 
evidence to determine whether there was coherence of associations 
across the scientific disciplines. They also assessed the biological 
plausibility of specific characteristics identified in epidemiologic 
studies as potentially conferring susceptibility to PM-related health 
effects.
The authors focused on the collective evidence evaluated in the 
most recent science review of the PM National Ambient Air Quality 
Standards and also built upon the evidence presented in previous 
reviews. The studies examined the health effects primarily due to 
both short- and long-term exposures to the fine and/or coarse frac-
tions of PM. 
Overall, the characteristics of populations most associated 
with increased susceptibility to PM-related health effects included 
1) life stage, specifically children and older adults; 2) preexisting 
cardiovascular and respiratory diseases; 3) specific genetic polymor-
phisms; and 4) low socioeconomic status, as measured by educational 
attainment and income. The authors found more limited evidence 
suggesting an increase in PM-related health effects in individuals 
with diabetes, chronic obstructive pulmonary disease, and increased 
body mass index. Potentially increased risks of PM-related health 
effects by sex and race/ethnicity also were indicated, although these 
associations were not consistent across health effects, PM size frac-
tions, or, in some instances, study locations.
The authors concede they are unable to clearly state the overall 
strength of the evidence for some characteristics of potentially 
susceptible populations due to inconsistent evidence across epidemio-
logic studies as well as lack of information from experimental studies 
regarding biologically plausible mechanisms. 
However, the novel integrative approach used to identify char-
acteristics of populations potentially susceptible to PM may be a 
valuable assessment tool for other air pollutants. The authors also 
propose a comprehensive definition of “susceptibility” to encompass 
all populations potentially at increased risk of adverse health effects 
as a consequence of exposure. Use of such a standardized defini-
tion could help reverse inconsistencies in terminology within the 
epidemiologic literature that may have complicated the identification 
of high-risk populations to date.
M. Nathaniel Mead, a science writer living in Durham, NC, has written for EHP since 2002.
Epigenetics of Formaldehyde
Altered microRNAs May Be Key to  
Adverse Effects
Formaldehyde has long been associated with asthma, acute respirato-
ry illness, and nasopharyngeal cancer. The International Agency for 
Research on Cancer has deemed it a known human carcinogen. A 
new study reveals evidence that epigenetic mechanisms may contrib-
ute to links between formaldehyde exposure and respiratory illness 
[EHP 119(4):494–500; Rager et al.]. The study authors discovered 
that formaldehyde disrupts levels of microRNAs, or miRNAs, small 
regulatory molecules that play a key role in gene expression. 
Ambient air contains formaldehyde given off from car exhaust, 
incinerators, and manufacturing and power plants. Formaldehyde 
also is widely used in preservatives and adhesives, including glue 
that binds plywood and particleboard, and it offgasses from 
furniture and building materials that use these products. 
Despite formaldehyde’s known respiratory toxicity, little is 
known about its mechanism of action related to disease. The 
authors of this study focused on miRNAs because earlier studies 
linked miRNA disturbances to a number of diseases includ-
ing blood and solid-tumor cancers. miRNAs act like molecular 
switches, turning on or off genes, including ones that lead to or 
protect from disease.
Nearly all the formaldehyde that humans inhale is absorbed 
in the respiratory tract because the gas is water-soluble and highly 
reactive. The authors therefore exposed human lung epithelial cells 
to formaldehyde gas at an air–liquid interface that mimics the 
human respiratory tract lining. 
Of more than 500 miRNAs assessed, formaldehyde signifi-
cantly downregulated 89 that are predicted to influence molecular 
signaling pathways relevant to cancer, inflammatory response, and 
endocrine system regulation, potentially representing a first step 
on the path toward disease. There is also preliminary evidence 
that the miRNAs that appeared to be most strongly affected by 
formaldehyde also may be altered in some cancer cells, suggesting a 
potential mechanism for the chemical’s carcinogenicity.
Cynthia Washam writes for EHP, Oncology Times, and other science and medical publications 
from South Florida.
Biomonitoring studies 
have shown that children 
are especially vulnerable 
to the health effects of 
PM exposure.The Pharmacokinetics of BPA 
Similarities in Human and Animal Metabolism 
Suggest Higher Exposure than Thought
Bisphenol A (BPA) has been shown to cause adverse health effects in 
animals, but attempts to extrapolate human health effects from this 
evidence are impeded by unanswered questions about routes and levels 
of exposure, metabolism, and whether animal models are appropriate 
proxies for humans. New findings show the kinetics of BPA metabolism 
are very similar in humans, monkeys, and mice and also suggest greater 
human exposure than previously estimated [EHP 119(4):422–430; 
Taylor et al.].
BPA in food and beverage packaging likely underlies most human 
oral exposure, and dermal and inhalation exposure may occur from 
other sources. BPA has been assumed to undergo rapid metabolism 
(conjugation) and clearance from the body. However, recent human 
biomonitoring data showed serum concentrations of unconjugated 
BPA, the bioactive form, at levels much higher than predicted given 
earlier assumptions about the amount of BPA ingested by humans and 
its expected rate of clearance.
The authors of the current study studied clearance of radiolabeled 
unconjugated BPA in rhesus macaques and CD-1 mice, then compared 
the results with those from a previous oral dosing study in women. In 
the first experiment, female monkeys received deuterated BPA (dBPA) 
at 400 µg per kg body weight once a day for a week. Blood samples were 
collected prior to dosing and several times on days 1 and 7. The second 
experiment involved an oral dose of 400 µg 3H-BPA per kg body weight 
to female CD-1 mice and measurements of the unconjugated compound 
in serum over the next 24 hours. A second group of mice received a single 
dose of varying amounts of  3H-BPA, with unconjugated serum levels 
measured 24 hours later, and a third group received a single dose of BPA 
at 100,000 µg/kg, with serum assessed for unconjugated BPA several 
times over the next 24 hours.
Unconjugated dBPA concentrations in monkeys averaged 0.5 ng/mL 
over 24 hours and peaked at 3.94 ng/mL 1 hour after treatment. These 
values are comparable to medians of 0.3–4.0 ng/mL reported in human 
biomonitoring studies. The amount of BPA needed to achieve the serum 
concentrations in monkeys far exceeded the 2007 U.S. Food and Drug 
Administration human exposure estimate of 0.16 µg/kg/day as well as the 
U.S. Environmental Protection Agency’s daily intake dose of 50 µg/kg. 
Results from the mouse experiments showed a linear relationship between 
BPA dose and unconjugated BPA in serum, with the kinetics of metabo-
lism remarkably similar to those observed in monkeys and humans.
If the reported plasma BPA concentrations in humans are accurate, 
the results suggest human exposure is currently underestimated and that 
there may be significant sources of exposure though non-oral routes. 
Additionally, they support CD-1 mouse studies as being relevant for 
estimating serum levels of unconjugated BPA in humans.
Julia R. Barrett, MS, ELS, a Madison, WI–based science writer and editor, has written for EHP 
since 1996. She is a member of the National Association of Science Writers and the Board of 
Editors in the Life Sciences.
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Where There Is Asbestos,  
There Is Mesothelioma
Filling in the Data Blanks
Malignant mesothelioma is caused almost exclusively by exposure 
to asbestos, and countries that have used asbestos nearly always have 
cases of mesothelioma. Tracking the disease has proved difficult, 
however, because not all developing countries that use asbestos col-
lect meso  thelioma incidence data. In a new global estimate of unre-
ported mesothelioma, researchers predict that at least one case of 
disease goes unreported for every four to five known cases worldwide 
[EHP 119(4):514–518; Park et al.].
The authors compared cumulative asbestos use from the 
U.S. Geological Study with disease cases reported to the World 
Health Organization. Because symptoms of mesothelioma 
often appear decades after exposure, the authors examined 
the relationship between the 15-year cumulative number of 
reported mesothelioma cases during 1994–2008 and cumula-
tive asbestos use during 1920–1970 among countries with 
data on both mesothelioma and asbestos use. The resulting 
relationship helped them predict the number of unreported 
mesothelioma cases in countries providing information on 
asbestos use but not on mesothelioma.
The authors found that cumulative asbestos use in 
89 countries totaled more than 65 million metric tons during 
1920–1970. Of the 56 countries also reporting mesothelioma 
data, there were more than 174,000 estimated cases and 92,000 
reported deaths during 1994–2008 (most mesothelioma patients 
succumb to the disease shortly after diagnosis, so numbers of 
new cases are very similar to numbers of deaths from the disease). 
When extrapolating these data to the 33 countries not reporting 
mesothelioma, the authors estimated an additional 39,000 cases 
would have occurred during that same 15-year period.
This estimate is conservative, say the authors, and they 
warn that because asbestos has a long industrial life span, and 
its use has quintupled since 1970, many countries should anticipate a 
higher disease burden in the years to come. The new study does not 
account for this 40-year increase. 
The authors propose that developed countries share their experience 
and technology to help developing countries better diagnose, report, 
and manage cases of mesothelioma. They also argue that all countries 
should move toward a complete ban on asbestos—although the long 
latency period means mesothelioma deaths would continue for decades, 
the disease would eventually disappear as asbestos use is phased out and 
exposure is eventually eliminated.
Rebecca Clay Haynes has written for EHP since 1993. Her work has also appeared on National 
Public Radio and in the Christian Science Monitor and The Environmental Forum. In addition, she is 
the author of two children’s science books related to astronomy and space exploration.
An asbestos factory in Ipubi, Pernambuco, 
Brazil, date unknown. Brazil has now 
banned asbestos production in this state, 
but mesothelioma’s long latency period 
means cases will continue to emerge  
for decades.